Treatment of Relapsed or Refractory AL Amyloidosis in a Daratumumab-Naive Patient
This protocol addresses patients with AL amyloidosis whose disease has relapsed or become refractory, and who have not previously received daratumumab. The absence of prior daratumumab exposure is the defining eligibility criterion that shapes the treatment approach in this setting.
Clinical Scenario
Relapsed or refractory AL amyloidosis in a patient with no prior daratumumab exposure. Confirming daratumumab-naive status is essential before selecting the treatment strategy for this population.
Treatment Approach (partial overview)
The preferred strategy in this setting incorporates a daratumumab-based regimen. Whether used as a doublet or triplet combination, daratumumab forms the backbone of treatment — the specific composition and sequencing are detailed in the full protocol.
Complete regimen details, combination partners, and clinical guidance are available in the full structured protocol below.
References
DOI: 10.1200/OP.22.00396
- If Dara-naive
- Dara-based regimen (doublet or triplet)
View source ↗